Jean-Claude Provost - 01 Mar 2024 Form 4 Insider Report for Lantheus Holdings, Inc. (LNTH)

Role
Chief Medical Officer
Signature
/s/ Eric Green, attorney-in-fact
Issuer symbol
LNTH
Transactions as of
01 Mar 2024
Net transactions value
$0
Form type
4
Filing time
05 Mar 2024, 20:20:00 UTC
Previous filing
06 Mar 2023
Next filing
07 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LNTH Common Stock Award $0 +18,564 +89% $0.000000 39,387 01 Mar 2024 By Theranostics Consulting SAS F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LNTH Stock Option (right to buy) Award $0 +10,998 $0.000000 10,998 01 Mar 2024 Common Stock 10,998 $64.64 By Theranostics Consulting SAS F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 6,188 restricted stock units that vest in equal installments over a three-year period and 12,376 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
F2 The option vests in three equal annual installments beginning on March 1, 2025.